ARTICLE INFO

Article Type

Original Research

Authors

Attarzadeh Hosseini   S.R. (*)
Rashid Lamir   A. (1)
Dehbashi   M. (1)






(*) Sport Physiology Department, Physical Education & Sports Sciences Faculty, Ferdowsi University of Mashhad, Mashhad, Iran
(1) Sport Physiology Department, Physical Education & Sports Sciences Faculty, Ferdowsi University of Mashhad, Mashhad, Iran

Correspondence

Address: Faculty of Physical Education and Sport Sciences, Ferdowsi University of Mashhad Paradise, Azadi Square, Mashhad, Iran. Postal Code: 91779-48979
Phone: +985138833910
Fax: +985138829580
attarzadeh@um.ac.ir

Article History

Received:  February  4, 2015
Accepted:  August 3, 2015
ePublished:  December 15, 2015

BRIEF TEXT


… [1-17] Most of the studies about doping and anabolic steroids show an increase in the consumption of the medications recently in Iran [18, 19]. Despite the fact, it is known that the athletes who consume the medications have not enough knowledge about doping and such medications and most of them assess injectable steroids highly morbid than the oral type [5, 6, 20].

Most of the studies about complications due to the consumption of the steroids criticize the medications without any investigation about their chemical structures and classifying them or investigate a particular steroid individually.

The aim of this study was to compare the effects of consumption of 17α-alkyl steroids and 17β-hydroxy steroids on the levels of liver enzymes and hematological factors in male bodybuilders.

This is a causal comparative study.

Bodybuilders resident in Mashhad (Iran) were studied in 2014.

24 athletes were studied via census method. PASS functions and NCSS software were used to estimate the sample size.

Anthropometric characteristics, type of the consumed steroid, and exercise history were collected using a researcher-made questionnaire. Based on the information, the subjects were divided into three 8-person groups including “consumers of oral steroids (17α-alkyl)” (group 1), “consumers of injectable steroids (17β-hydroxy)” (group 2), and “athletes without any AAS consumption history” (group 3). The subjects were without any inherited hematological or liver disease and all of them had not had any drug or drugs containing alcohol. Consumption period of the steroids in two consumption groups were 8 weeks. In the first group, the used medication forms were dianabol, methandienone, oximetallon, metan, and winstrol tablets all of which had 17α-alkyl structure. In the second group, the used medications were nandrolone decanoate, testosterone enanthate, sustanon, and testosterone propionate all of which had 17β-hydroxy structure. After 12-hour fasting, the subjects were in the laboratory for blood sampling. ALT, AST, ALP enzymes were measured using a kit (ParsAzmoon; Iran) via DGKC and IFCC methods with an auto-analyzer device (CRONIX 801-AT; Germany). A counter device (Diatron; Austria) was used to determine CBC. Data was analyzed using SPSS 19 software. Shapiro-Wilk test was used to investigate normal data. Homogeneity of the variances having been confirmed by Leven’s test, the groups were compared with each other using One-way ANOVA and post-hoc tests.

Mean age, height, and weight of the subjects were 25.49±4.80years, 174.38±9.20cm, and 74.68±11.7kg, respectively. Aspartate aminotransferase and alanine aminotransferase enzymes in the first group were significantly higher than other groups. There was no significant difference in the levels of phosphatase alkaline, despite a higher level in the first group than others. Number of red blood cells in the second group (using injectable steroids) was significantly higher than control group. Number of red blood cells was significantly higher than the group consuming oral steroids. Hemoglobin and hematocrit in the group using injectable steroids were significantly higher than other groups. There was no significant difference in other factors such as WBC, MCV, MCH, MCHC, and PL between the groups (Table 1).

There was an increase in the serum levels of ALT and AST enzymes in the group consuming oral steroids (17α-Alkyl) than other groups. In athletes consuming the medications, most changes are in AST and ALT enzymes, while there is not any considerable change in the level of ALP [21, 22]. … [23] There are liver cholestasis and toxicity, as well as an increase in the liver enzymes due to AAS consumption, in three athletes [24]. Toxicity of 17α-alkyl group has been confirmed compared to 17β medication group, in such case that non-alkyl steroids have shown no liver complication in similar doses [25]. Similarly, in the present study, the group using injectable steroids (17β) underwent no considerable changes and there was no considerable increase in the levels of AST and ALT enzymes in the group unlike the first group. There were significant increases in some factors such as red blood cells, hematocrits, and hemoglobin in the groups consuming steroids especially in the second group. The results are consistent with many studies [26]. There are significant increases in hematocrit and hemoglobin due to the consumption of testosterone enanthate [26]. … [27-29] There was no significant difference in other hematologic factors such as WBC, PLT, MCV, and neutrophil. The results are consistent with other studies [13, 30]. … [31-33]

Comprehensive training programs should be compiled to enhance the athletes’ knowledge about the consequences of AAS consumption.

Lack of enough true information about the consumed medications by the athletes and a homogeneous sample were of the limitations for the present study.

There are increases in the levels of AST and ALT liver enzymes only due to the consumption of oral steroids (17α-alkyl), while any increase in the levels of erythrocyte, hematocrit, and hemoglobin is expectable due to any medication consumption.

All the participants and staff of the medical laboratory are appreciated.

Non-declared

Due no encouraging the athletes to consume AAS, no intervention by the researcher, and using pretest-posttest methods, there is no specific ethical situation.

The study was funded by Research Deputy of Mashhad Ferdosi University.

TABLES and CHARTS

Show attach file


CITIATION LINKS

[1]Lundholm L, Käll K, Wallin S, Thiblin I. Use of anabolic androgenic steroids in substance abusers arrested for crime. Drug Alcohol Depend. 2010;111(3):222-6.
[2]Street C, Antonio J, Cudlipp D. Androgen use by athletes: A reevaluation of the health risks. Can J Appl Physiol. 1996;21(6):421-40.
[3]Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513-54.
[4]Sobolevsky T, Rodchenkov G. Detection and mass spectrometric characterization of novel long-term dehydrochloromethyltestosterone metabolites in human urine. J Steroid Biochem Mol Biol. 2012;128(3-5):121-7.
[5]Maravelias C, Dona A, Stefanidou M, Spiliopoulou C. Adverse effects of anabolic steroids in athletes: A constant threat. Toxicol Lett. 2005;158(3):167-75.
[6]Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther. 2001;23(9):1355-90.
[7]Marocolo M, Maior AS, Katayama PL, da Mota GR, Neto OB, de Assis A, et al. Anabolic steroid treatment induces cardiac autonomic dysfunction in rats: Time-course of heart rate variability. Am J Biomed Eng. 2013;3(3):54-62.
[8]Hajimoradi B, Kazerani H. Echocardiographic findings in power athletes abusing anabolic androgenic steroids. Asian J Sports Med. 2013;4(1):10-4.
[9]Graham MR, Grace FM, Boobier W, Hullin D, Kicman A, Cowan D, et al. Homocysteine induced cardiovascular events: A consequence of long term anabolic-androgenic steroid (AAS) abuse. Br J Sports Med. 2006;40(7): 644-8.
[10]Peters MA, Phelps L. Body image dissatisfaction and distortion, steroid use, and sex differences in college age bodybuilders. Psychol Sch. 2001;38(3):283-9.
[11]Neri M, Bello S, Bonsignore A, Cantatore S, Riezzo I, Turillazzi E, et al. Anabolic androgenic steroids abuse and liver toxicity. Mini Rev Med Chem. 2011;11(5):430-7.
[12]Symons TB, Sheffield-Moore M, Mamerow MM, Wolfe RR, Paddon-Jones D. The anabolic response to resistance exercise and a protein-rich meal is not diminished by age. J Nutr Health Aging. 2011;15(5):376-81.
[13]Dorry K, Nedaeinia R, Hemayatkhah Jahromie V, Naderian M. The effects of anabolic-androgenic steroid drugs consumption on blood factors in Jahrom. Med Lab J. 2010;4(1):21-29. [Persian]
[14]Jalilian F, Allahverdipour H, Moeini B, Barati B, Moghimbeigi A, Hatamzadeh N. Relation of self-efficacy and perceived behavior control on gym users’ anabolic steroid use related behaviors. Sci J Hamadan Univ Med Sci. 2012;19(1):45-52. [Persian]
[15]Frahm KA, Lumia AR, Fernandez E, Strong R, Roberts JL, McGinnis MY. Effects of anabolic androgenic steroids and social subjugation on behavior and neurochemistry in male rats. Pharmacol Biochem Behav. 2011;97(3):416-22.
[16]Giannini EG, Testa R, Savarino V. Liver enzyme alteration: A guide for clinicians. Can Med Assoc J. 2005;172(3):367-79.
[17]Socas L, Zumbado M, Perez-Luzardo O, Ramos A, Perez C, Hernandez J, et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: A report of two cases and a review of the literature. Br J Sports Med. 2005;39(5):27-35.
[18]Arazi H, Hosseini R. The prevalence of anabolic-androgenic steroids abuse, knowledge and attitue of their side effects, and attitude toward them among the bodybuilding athletes in Rasht. J Guilan Univ Med Sci. 2012;20(80):34-41. [Persian]
[19]Allahverdipour H, Jalilian F, Shaghaghi A. Vulnerability and the intention to anabolic steroids use among Iranian gym users: An application of the theory of planned behavior. Subst Use Misuse. 2012;47(3):309-17.
[20]Martin NM, Abu Dayyeh BK, Chung RT. Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage. World J Gastroenterol. 2008;14(28):4573-5.
[21]Stimac D, Milic S, Dintinjana RD, Kovac D, Ristic S. Androgenic/Anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol. 2002;35(4):350-2.
[22]Timcheh-Hariri A, Balali-Mood M, Aryan E, Sadeghi M, Riahi-Zanjani B. Toxic hepatitis in a group of 20 male body-builders taking dietary supplements. Food Chem Toxicol. 2012;50(10):3826-32.
[23]Filipowicz R, Greene T, Wei G, Cheung AK, Raphael KL, Baird BC, et al. Associations of serum skeletal alkaline phosphatase with elevated C-reactive protein and mortality. Clin J Am Soc Nephrol. 2013;8(1):26-32.
[24]Chahla E, Hammami MB, Befeler AS. Hepatotoxicity associated with anabolic androgenic steroids present in over-the-counter supplements: A case series. Int J Appl. 2014;4(3):75-82.
[25]Welder AA, Robertson JW, Melchert RB. Toxic effects of anabolic-androgenic steroids in primary rat hepatic cell cultures. J Pharmacol Toxicol Methods. 1995;33(4):187-95.
[26]Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914-9.
[27]Parkinson AB, Evans NA. Anabolic androgenic steroids: A survey of 500 users. Med Sci Sports Exerc. 2006;38(4):644-51.
[28]Golestani R, Slart RH, Dullaart RP, Glaudemans AW, Zeebregts CJ, Boersma HH, et al. Adverse cardiovascular effects of anabolic steroids: Pathophysiology imaging. Eur J Clin Invest. 2012;42(7):795-803.
[29]Young AJ, Sawka MN, Muza SR, Boushel R, Lyons T, Rock PB, et al. Effects of erythrocyte infusion on VO2max at high altitude. J Appl Physiol. 1996;81(1):252-9.
[30]Tsiara S, Chaidos A, Gouva M, Christou L, Panteli K, Kapsali E, et al. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone. J Exp Clin Cancer Res. 2004;23(1):47-52.
[31]Schwingel PA, Cotrim HP, Salles BR, Almeida CE, dos Santos CR Jr, Nachef B, et al. Anabolic‐androgenic steroids: A possible new risk factor of toxicant‐associated fatty liver disease. Liver Int. 2011;31(3):348-53.
[32]Nascimento JH, Medei E. Cardiac effects of anabolic steroids: Hypertrophy, ischemia and electrical remodelling as potential triggers of sudden death. Mini Rev Med Chem. 2011;11(5):425-9.
[33]Harston GW, Batt F, Fan L, Okell TW, Sheerin F, Littlewood T, et al. Lacunar infarction associated with anabolic steroids and polycythemia: A case report. Case Rep Neurol. 2014;6(1):32-9.